UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look

Cancer discovery, 2011-09, Vol.1 (4), p.291-296

2011

Volltextzugriff (PDF)

Magnetic resonance imaging of tumor response to stroma-modifying pegvorhyaluronidase alpha (PEGPH20) therapy in early-phase clinical trials

Scientific reports, 2024-05, Vol.14 (1), p.11570-11570, Article 11570

2024

Volltextzugriff (PDF)

Dose-response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin

Scientific reports, 2020-09, Vol.10 (1), p.14449, Article 14449

2020

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Journal of clinical oncology, 2001-07, Vol.19 (13), p.3267-3279

2001

Volltextzugriff (PDF)

CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy

Molecular cancer therapeutics, 2012-04, Vol.11 (4), p.994-1005

2012

Volltextzugriff (PDF)

Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies

Journal of clinical oncology, 2005-11, Vol.23 (31), p.7785-7793

2005

Volltextzugriff (PDF)

The hedgehog knows many tricks

Current drug targets, 2011-12, Vol.12 (14), p.2091-2095

2011

Volltextzugriff (PDF)

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors

Clinical cancer research, 2016-07, Vol.22 (13), p.3157-3163

2016

Volltextzugriff (PDF)

Does intraosseous equal intravenous? A pharmacokinetic study

The American journal of emergency medicine, 2008, Vol.26 (1), p.31-38

2008

Volltextzugriff (PDF)

Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

Clinical cancer research, 2011-04, Vol.17 (8), p.2502-2511

2011

Volltextzugriff (PDF)

A Phase I Pharmacokinetic Study of HMN-214, a Novel Oral Stilbene Derivative with Polo-Like Kinase-1–Interacting Properties, in Patients with Advanced Solid Tumors

Clinical cancer research, 2006-09, Vol.12 (17), p.5182-5189

2006

Volltextzugriff (PDF)

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Cancer discovery, 2017-07, Vol.7 (7), p.704-715

2017

Volltextzugriff (PDF)

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

British journal of cancer, 2018-01, Vol.118 (2), p.153-161

2018

Volltextzugriff (PDF)

CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin

Molecular cancer therapeutics, 2011-10, Vol.10 (10), p.1929-1938

2011

Volltextzugriff (PDF)

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors

The oncologist (Dayton, Ohio), 2019-01, Vol.24 (1), p.14-e10

2019

Volltextzugriff (PDF)

A Historical Perspective of Anthracycline Cardiotoxicity

Heart failure clinics, 2011-07, Vol.7 (3), p.363-372

2011

Volltextzugriff (PDF)

DNA minor groove binders: Back in the groove

Cancer treatment reviews, 2009-08, Vol.35 (5), p.437-450

2009

Volltextzugriff (PDF)

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

Clinical cancer research, 2018-09, Vol.24 (17), p.4072-4080

2018

Volltextzugriff (PDF)

Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding

Clinical cancer research, 2011-04, Vol.17 (8), p.2512-2520

2011

Volltextzugriff (PDF)

Targeting the nucleolus for cancer-specific activation of p53

Drug discovery today, 2014-03, Vol.19 (3), p.259-265

2014

Volltextzugriff (PDF)

Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors

Investigational new drugs, 2018-02, Vol.36 (1), p.85-95

2018

Volltextzugriff (PDF)

Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours

European journal of cancer (1990), 2014-11, Vol.50 (17), p.2897-2904

2014

Volltextzugriff (PDF)

Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Clinical cancer research, 2013-03, Vol.19 (5), p.1232-1243

2013

Volltextzugriff (PDF)

A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors

Clinical cancer research, 2013-01, Vol.19 (1), p.268-278

2013

Volltextzugriff (PDF)

Squalamine Treatment of Human Tumors in nu/nu Mice Enhances Platinum-based Chemotherapies

Clinical cancer research, 2001-03, Vol.7 (3), p.724-733

2001

Volltextzugriff (PDF)

1 – 25 von 128

Suche als RSS-Feed

Aktive Filter

ThemaNeoplasms - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(122)
Mit Volltextzugriff
(114)

Publikationsform

Artikel
(128)

Sprache

Englisch
(128)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Humans
(127)
Science & Technology
(107)
Life Sciences & Biomedicine
(105)
Oncology
(94)
Female
(86)
Male
(80)
Aged
(76)
Middle Aged
(76)
Adult
(73)
Biological And Medical Sciences
(72)
Medical Sciences
(72)
Pharmacology. Drug Treatments
(70)
Antineoplastic Agents
(68)
Chemotherapy
(59)
Dose-Response Relationship, Drug
(39)
Drug Administration Schedule
(31)
Neoplasms - Pathology
(31)
Antineoplastic Agents - Adverse Effects
(30)
Antineoplastic Agents - Therapeutic Use
(27)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look

Magnetic resonance imaging of tumor response to stroma-modifying pegvorhyaluronidase alpha (PEGPH20) therapy in early-phase clinical trials

Dose-response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy

Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies

The hedgehog knows many tricks

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors

Does intraosseous equal intravenous? A pharmacokinetic study

Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

A Phase I Pharmacokinetic Study of HMN-214, a Novel Oral Stilbene Derivative with Polo-Like Kinase-1–Interacting Properties, in Patients with Advanced Solid Tumors

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors

A Historical Perspective of Anthracycline Cardiotoxicity

DNA minor groove binders: Back in the groove

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding

Targeting the nucleolus for cancer-specific activation of p53

Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors

Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours

Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors

Squalamine Treatment of Human Tumors in nu/nu Mice Enhances Platinum-based Chemotherapies

Aktive Filter

Suchergebnisse filtern